The pharmaceutical community is excited about ZPHC Retatrutide 120 , a dual-action treatment showing significant results in clinical research. This groundbreaking compound, a GLP-1 receptor agonist alongside a GIP agent , appears to notably reduce body mass and positively affect metabolic markers